

ROLE OF PROBIOTICS IN COVID 19 – A REVIEW

Dr. Luxita Sharma¹, Shazi Ali², H. David³, Dr. Dhananjay Sharma⁴

¹Associate Professor, Department of Dietetics and Applied Nutrition, Amity Medical School, Amity University Haryana, India

²Department of Dietetics and Applied Nutrition, Amity Medical School, Amity University Haryana, India

³Department of Dietetics and Applied Nutrition, Amity Medical School, Amity University Haryana, India

⁴Assistant Professor, Department of Dietetics and Applied Nutrition, Amity Medical School, Amity University Haryana, India

Corresponding Author

Dr. Luxita Sharma, Associate Professor, Department of Dietetics and Applied Nutrition, Amity Medical School, Amity University Haryana, India.

Article History:

Received : 08-10-2024

Accepted : 25-11-2024

Available Online: 30-12-2024

How to Cite the Article:

Dr. Luxita Sharma, et al. *ROLE OF PROBIOTICS IN COVID 19 – A REVIEW*, *Anesthesia and Pain Medicine*. 2024; 19(4):

ABSTRACT

Coronavirus which is brought about by SARS-CoV-2 is worldwide pandemic which starts at the beginning of 2020 in China and have affected many countries and have taken many lives worldwide. Despite numerous efforts on social distancing, vaccines, lockdowns, it is still increasing. Fever, hack, tiredness, and loss of taste or smell are commonplace side effects. Two or three optional impacts like trouble breathing or windedness, loss of talk, or movability, or disarray, serious chest pain, and requires quick clinical action. Its symptoms cannot be fully prevented but getting vaccinated, social distancing, wearing fitted mask, well ventilated spaces, washing hands regularly, covering mouth when coughing or sneezing and self-isolating if unwell can helps in protection and spreading of the virus. Probiotics are live organisms which alter the gut microbiome and claim that interferon production and gut homeostasis serve as antiviral defenses. They also help in stabilizing gut micro biodata within the gut. Probiotics like *Lactobacillus* and *Bifidobacterium* are widely and commonly used. Scientific evidence has also proved that probiotics has antiviral and immune boosting effects on health. The properties of Probiotics can be used to combat COVID 19. Here, in this review we will be discussed about the roles of Probiotics in different health and disease, their anti-viral activity and anti-inflammatory activity. What and how different live probiotics bacterial are tested for treatment of different diseases base on case studies.

Keywords: Covid 19, SARS-CoV-2, Probiotics, *Lactobacillus*, *Bifidobacterium*

INTRODUCTION

Coronavirus is a worldwide pandemic infection brought about by serious intense respiratory disorder -2s (SARS-CoV-2). It also caused severe respiratory inflammatory disease (Wang, C *et al.*, 2020). SARS-CoV-2, an exceptionally pathogenic new zoonotic individual from the SARS-CoV family that likewise incorporates SARS-CoV-1 and the Center East respiratory condition Covid (MERS-CoV), is the infection that causes Coronavirus. These infections contaminate the both birds and warm blooded creatures.

Coronavirus disease started in China in late December 2019 (Eurosurveillance Editorial Team., 2020). Small molecules such as hydroxychloroquine which can prevent entry or replication is being studied for prevention of the virus (Yazdany& Kim., 2020) To prevent inflammation the study of tocilizumab and interferon-beta are also being tested. (Liu *et al.*, 2020). Coronavirus has a major impact on global level in terms of economic, global public health resources, and human health (Gorbalenya, *et al.*, 2020). Dry cough and dyspnea are the most prevalent clinical signs of SARS-CoV-2 infection, followed by fever ,exhaustion and myalgia. Additional symptoms include gastrointestinal issues, a headache, a sore throat, and rhinorrhoea. The most predominant and serious side effect of the ailment seems, by all accounts, to be pneumonia (Guan *et al.*, 2020).

Coronavirus are enveloped, positive sense single-strand RNA infections that have a place with the wide family Coronaviridae and subfamily Caronavirinae. These viruses genomic sizes range from 26 to 32 kb (Gorbalenya, *et al.*,

2020). The spike (S) glycoprotein of SARS-CoV-2 cooperates with ACE2 receptors on cells to tie to them. S1 and S2 are two of the S protein's areas. S2 catalyzes the film mix, conveying the inherited material into cells, while S1 joins to the peptidase area of ACE2, thusly the adage "receptor-binding domain" (RBD) (Hoffmann *et al.*, 2020). Non-structural proteins are projected to be among them and to take part in host-protein interactions as well as to modify host-cell signaling cascades (Guan *et al.*, 2020). In spite of executing different plans and severe general wellbeing like social removing, lockdowns and isolations, the quantity of contaminations is as yet rising. SARS-CoV-2 is new and unique in relation to other Covids (Hassan *et al.*, 2020). It requires newly developed and researched vaccines as the present vaccines are not effective against it (Ceviket *et al.*, 2020). The disease keeps transforming and appearing in suggestive, presymptomatic and asymptomatic designs in affected masses (Sadiq, 2021; Antunes., 2020).

Probiotics are live microorganisms which take part in digestion and working on microbial equilibrium in the stomach. No less than 106 practical CFU/g are viewed as adequate amount (Mack., 2005; Bezirtoglou & Stavropoulou., 2011; Marinova *et al.*, 2019). Probiotics are additionally gainful for a few potential instruments which incorporates immunomodulation, epithelial obstruction capability upkeep, and sign transduction balance (Wan *et al.*, 2016). *Lactobacillus*, *Bifidobacterium*, *Leuconostoc*, *Pediococcus*, and *Enterococcus* are remembered for probiotics. Individuals normal stomach microflora is made up basically of microorganisms from the genera *Lactobacillus* and *Bifidobacterium*. They are for the most part used in yogurts and other dairy things as it protected to utilize (López-Moreno & Aguilera., 2020). Probiotics help to keep up with the legitimate equilibrium of the host's protective immune reaction, which thus works on the capability of the mucosal obstruction and modifies the immune system (El Hage., 2017). Probiotics can save the uprightness of the mucosal boundary and reduce stomach mucosal bothering through the vitamin D axis (Li *et al.*, 2015). Moreover, Probiotics have some control over the natural and versatile insusceptible frameworks by means of the vitamin D hub (Del Pinto, R *et al.*., 2017). Probiotics, particularly lactic acid bacteria strains, have the ability to modify the human gut microbiota by inhibiting the growth of bacteria (Khaneghahet *et al.*, 2020). Hence, a viable strategy to reduce food-borne enteric infections could involve the introduction of probiotic strains as well as the encouragement of their proliferation and activity in the gut. Probiotics have also been found to boost immunity, lessen the severity of various allergy disorders, and have some anticarcinogenic qualities, in addition to providing a host of additional health advantages outside of the stomach (Khaneghahet *et al.*, 2020). The GI tract is home to over 70% of the body's resistant cells, showing an immediate connection between the invulnerable framework (immune system) and gastrointestinal microbiota, which might have a few cooperations with GI infections (Rajput *et al.*, 2021). Studies have shown that *Lactobacillus* and *Bifidobacterium* have an immunomodulatory influence against rotavirus (RV), one of the most widely recognized reasons for perilous the runs in kids younger than five (Rodriguez *et al.*, 1980; Tate *et al.*, 2016). RV changes the human stomach microbiota by making Firmicutes the overwhelming phylum rather than Bacteroidetes, diminishing bacterial variety, and helping sharp microorganisms such the genera *Shigella* (Ma *et al.*, 2016). The response of probiotics on RV might be impacted by the dietary condition of weight list, including typical weight, underweight, and overweight (Pant *et al.*, 2007). Probiotics and microbiota have likewise been displayed to antivirally affect respiratory infections, for example, the occasional executioner flu infection, notwithstanding gastrointestinal infections (Lehtoranta *et al.*, 2014). Probiotics that are inhaled or taken orally have been shown to increase resistance to respiratory virus infections, according to growing body of research (Jung *et al.*, 2017). Natural killer (NK) cell counts and activity in the blood both considerably increase (Grudzien & Rapak, A. 2018). Probiotics can likewise animate the development of supportive of and mitigating cytokines by APCs in light of unfamiliar particles by enacting versatile resistance. The mitigating cytokine IL-10, which is created by a few invulnerable initiated cells, restrains digestive irritation administrative supportive of fiery cytokines, chemokines, and their receptors (Azad *et al.*., 2018). Probiotic use may reduce or change the risk of respiratory health infection by improving gut immunity (Wang *et al.*, 2016). Probiotics help lung resistance by further developing the T administrative reaction in the aviation route (Mortazet *et al.*, 2013). Utilization of probiotics decreases the rate of respiratory plot contamination in young people (Araujo *et al.*, 2015). The utilization of probiotics fundamentally diminishes the risk of cold and abbreviates the length of respiratory plot disease side effects (Wang *et al.*, 2016). In addition, probiotics played a significant part in seriously populating the stomach to prohibit microorganisms, as well as adjusting stomach hindrance capability and penetrability. Probiotics have recently been found to support neutrophil, leukocyte, and regular executioner cell numbers and action, as recently referenced. Probiotics have mitigating characteristics and assist with staying away from bacterial super-ailments during viral diseases. Butyrate, a metabolite of probiotics, has been found in the gateway dissemination. It cooperates to a G protein coupled receptor on leucocytes (free unsaturated fat receptor 2), expanding pneumonic macrophage expansion and dendritic cell movement. They help to create a Th2 safe response in the lungs. In excess of twenty probiotics have been displayed to increment calming interleukins and against viral immunizer creation, bringing down viral burden. In Coronavirus patients, probiotics could help to re-establish the modified stomach vegetation, prompting a solid stomach lung pivot. They could likewise restrict bacterial movement across the stomach mucosa, trying not to cover contaminations. Thus, to forestall serious results in Coronavirus patients, like ARDS with Father and multi-organ disappointment condition, the immunomodulatory activities of probiotics might be huge (MOF). Probiotics may likewise keep the infection from reproducing and from entering the host cells. *Bifidobacterium animalis* has an enemy of interleukin activity that forestalls Covid increase. IL-17 articulation is initiated by *Lactobacillus casei* ATCC 39392 during Covid gastroenteritis (Santacroce *et al.*, 2021).

Role of probiotics in health and disease

1 Reducing Cholesterol Levels

Probiotics have the ability to reduce cholesterol levels, improve urogenital and vaginal health, oral health and management and treatment of lactose intolerance. *Regarding how probiotics decrease cholesterol levels, several theories have been put out. The most by and large recognized of the overall huge number of speculations is the bile salt hydroxylase thought. Hepatocytes in the liver make bile salts that make it simpler for cholesterol and fat from food to get across the digestive epithelium. Glycine and the significant bile acids join form glycocholic acid (cholyglycine) and taurocholic acid, separately. Since the formed bile salts are uncommonly dissolvable, following maintenance, the greater part of them enter the enterohepatic course, causing an improvement in the blood (McAuliffe et al., 2005).* Since free fundamental bile acids are less really reabsorbed from the stomach related lumen and are eliminated in feces, probiotics BSH could hydrolyse shaped bile acids to convey them (Lye et al., 2010; Huang et al., 2013). These probiotics with active BSH boost bile salt production from cholesterol in their colonised region, hence lowering issues related to high cholesterol.

Since the cholesterol bringing down capacity of probiotic is strain specific (Ishimwe et al., 2015), it's still necessary to identify strains with exceptional qualities.

2 Protection of Genital infections

Lactobacillus species assume an extraordinary part in security against genital contaminations in ladies. UTIs, yeast vaginitis, candidiasis, bacterial vaginosis, and other infections involving an imbalance in the urogenital microbial flora can occur repeatedly (Lee, 2014). It has been demonstrated that lactobacilli create biosurfactants and proteins that bind to collagen to prevent pathogen attachment to cells. This might explain why lactobacilli dominate the vaginal mucosa, rendering it less susceptible to infections (Waigankar & Patel, 2011). At this point, just Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri strains have been clinically displayed to make a difference (Commene et al, 2005), at the point when given intravaginally once week after week or two times day to day orally, UTI repeats were diminished in patients, and a typical vaginal flora dominated by lactobacilli was reestablished (Reid & Bruce, 2006). Supplemental probiotics support the colonization of favorable microbiota and may assist with chipping away at in everyday vaginal well-being (Vujic et al., 2013) and daily oral use of Lactobacillus fermentum and L. rhamnosus has also been proven to alter the vaginal flora (Reid et al., 2001).

The human mouth is home to an assortment of microbiomes, including microorganisms, infections, organism, protozoa, and archaea. A greatness of pathogenic natural elements can cause a combination of oral clinical issues, including dental caries, periodontitis, and halitosis since the balance of this huge number of microorganisms is promptly disturbed (Elavarasu et al., 2012). Bifidobacterium and Lactobacillus species are included in probiotics sold for dental health (Banas & Popp, 2013).

3 Lactose Intolerance

Lactose narrow mindedness (LI) or lactose malabsorption happens when milk is polished off and the small digestive system can't produce satisfactory lactase. Most mammalian children can switch lactose over totally for a changed time period after birth, making lactose a crucial sustenance for all babies. Colonic minuscule creatures accordingly separate any additional lactose, delivering hydrogen, methane, and short-chain unsaturated fats along these lines (Barling, 2012). Yogurt contains microbial galactosidase, which is known to endure stomach travel and help in lactose assimilation. Milk containing L. acidophilus additionally assists lactose assimilation in people with LI, and overproducing - galactosidase mutants mitigated side effects of lactose malabsorption (Ibrahim & O'Sullivan, 2000; Goh & Klaenhammer, 2013). Additionally, probiotic administration can change the composition of the colon's microbiota and reduce symptoms in people who are lactose intolerant (Fox-Orenstein & Chey, 2012). One way that lactose intolerance may be reduced by supplementation is through changes to the intestinal flora. Also, probiotic plans for helpful use are more compelling when probiotics and prebiotics are joined (known as synbiotics) (Baek & Lee, 2009).

4 Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a constant disease that fundamentally brings down the personal satisfaction of people experiencing it (Cain et al., 2006; Ford et al., 2007). Irritable bowel syndrome (IBS) influences 3% to 25% of everyone in general population (Cremonini & Talley 2005). The objective of treatment is to reduce side effects since there is no fix, , although this objective is habitually met with restricted achievement. Probiotics (fortifying microscopic organisms consumed to advance wellbeing), which have been displayed to adjust the typical stomach microbiota in IBS, might be useful in facilitating side effects (McFarland & Dublin 2008). Bifidobacterium infantis had extensive enhancements in swelling/distension, gut movements, or potentially stomach torment/uneasiness when contrasted with those utilizing a fake treatment. To learn how much (and in which IBS subpopulations) certain probiotics are helpful treatment techniques

in the administration of IBS side effects, more RCTs with proper ultimate objectives and configuration are required (Sanders *et al.*, 2013).

5 Infectious diarrhoea

In the USA, pediatric loose bowels influence 16.5 million kids younger than 5 consistently and is a significant reason for death in emerging countries (McFarland, 2010). Additionally, the significant reasons for disease and passing among kids younger than five internationally are intestinal and diarrheal problems (Black *et al.*, 2010). Pediatric loose bowels has been considered with an assortment of probiotic strains, including *Lactobacillus rhamnosus* GG, *Saccharomyces boulardii*, and mixes of different probiotic strains. 78% of the 54 RCTs that were led, which tried 8 particular single strains and different mixes of 2-4 strains, uncovered massive impacts for pediatric looseness of the bowels (McFarland, 2010). Various preliminaries utilizing probiotics have shown diminished frequency of nosocomial loose bowels, as well as diminished anti-toxin related the runs and repeats of *Clostridium difficile*-related loose bowels. These probiotics incorporate *Saccharomyces boulardii*, *Lactobacillus rhamnosus* GG, and different strains (Guarino *et al.*, 2015). By adding *B. bifidum* and *Streptococcus thermophilus* to new-born formula, episodes of acute infectious diarrhoea were less frequent (Saavedra *et al.*, 1994). However probiotics might lessen nosocomial contaminations in certain populaces, but they are not right now exhorted for use in critically sick hospitalized patients (Barraud *et al.*, 2010; Besselink *et al.*, 2008).

6 Cancer and cancer therapies

Colorectal disease (CRC) is one of the most widely recognized tumors around the world (Sanders *et al.*, 2013). *Lactobacillus*-enriched diets can lower the risk of colorectal cancer by 37% compared to controls (Goldin & Gorbach, 1980). Appropriately, the two probiotics can be used in down to earth food sources or for the treatment or aversion of CRC (Thirabunyanon *et al.*, 2009).

Probiotics effect on immune health (Antiviral activity, anti-inflammatory activity)

The gastrointestinal tract's principal capability is to process and assimilate supplements to satisfy the metabolic requests and necessities for appropriate human development and advancement. Moreover, the gastrointestinal mucosa goes about as the body's most memorable line of safeguard against the antigens that are continually present in the stomach lumen because of food and organisms (Sanderson & Walker, 1993). Probiotic organisms can affect the invulnerable immune system by overhauling the host's customary safeguard. Different immunological limits, including humoral, cell, and dubious opposition, have been demonstrated to be defenseless to adjustment by probiotic microorganisms (Matsuzaki *et al.*, 1998; Matsuzaki & Chin, 2000; Madsen *et al.*, 2001; Chiang *et al.*, 2000; Gill *et al.*, 2001; Cross *et al.*, 2002).

1 Antiviral Activity

The virus is a sub microscopic infectious agent that affects both people and animals. It only replicates inside the live cells of an organism. The genetic makeup of the majority of viruses is either RNA or DNA. The nucleic acid might have one or two strands. Numerous lethal infections, such as those caused by the Zika virus, Ebola virus, influenza virus, herpes simplex virus (HSV), hendra virus, and coronavirus, are caused by viruses (Khusro *et al.*, 2018; Khusro *et al.*, 2020; Khusro *et al.*, 2020).

The association of the virion to the cell surface and the conveyance of the viral genome to the site of replication are two cycles in the viral segment into the human body and the improvement of illnesses. Hence, getting through the cellular membrane is the critical stage in infection attack. (Helenius, 2018).

immune system's defences (Hardy, 2013). Then again, probiotic microbes that are available in matured food sources produce bioactive substances that are significant in supporting the antiviral action. Accordingly, the probiotics have been named Immunobiotics because of their antiviral capability (Villena, 2016). Due to the two or three clinical assessments that have detailed the regular confirmation from now forward, endlessly a really long time, the antiviral action of developed food sources isn't unquestionably known (Aslam *et al.*, 2020).

The probiotic *Lactobacillus casei* Shirota had the option to rapidly clear HPV-related cervical sores and effectively kill the disease in people with HPV and poor quality squamous intraepithelial sores. The half year intercession by *L. casei* Shirota gave novel techniques to cervical malignant growth counteraction and treatment as well as a huge decrease in HPV contaminations (Verhoeven *et al.*, 2013). By changing the proportion of proinflammatory to calming cytokines, probiotic microscopic organisms are fundamental for supporting resistant reactions and reducing illness in the human host (Infusino *et al.*, 2020; Sundararaman, 2020).

SUBJECTS	PROBIOTICS BACTERIA	AMOUNT	EFFECTS	REFERENCES
HEALTHY SUBJECTS	<i>Lactobacillus plantarum</i> HEAL and <i>Lactobacillus paracasei</i> 8700:2	9 10^9 CFU per day for 12 weeks	- reduced the incidence of the common cold and its symptoms significantly in healthy subjects - The total cold symptoms score and pharyngeal symptoms were also reduced during the probiotic treatment - could prevent or nullify the severity of the common cold	Berggren <i>et al</i> , 2011
HEALTHY ADULTS (18–60 YEARS OLD)	<i>L. casei</i> 431	10^9 CFU per day for 42 days	could reduce the number of episodes of upper RTIs in healthy adults	Jespersen <i>et al</i> , 2015
BOTH ADULT AND OLDER SUBJECTS	<i>Bifidobacterium longum</i> bv. <i>infantis</i> CCUG 52486 and gluco-oligosaccharide	10^9 CFU per day and 8 g per day for eight weeks	increased the total antibody titers, influenza-vaccine-specific IgA, IgM and IgG levels in both adult and older subjects.	Przemski-Kosicka <i>et al</i> , 2016
HEALTHY SUBJECTS	GanedenBC ³⁰ (<i>Bacillus coagulans</i> GBI-306086)	2×10^9 CFU of probiotics for 30 days	treatment of respiratory viral infection	Baron, 2009
THE CHILDREN (2–6 YEARS OLD)	<i>L. rhamnosus</i> 35	2 or 6×10^8 CFU for three days	reduced about 86% of the fecal viral shedding in children.	Fang <i>et al</i> , 2009
NURSING HOME RESIDENTS	<i>L. rhamnosus</i> GG and a mixture (1:1) of galactooligosaccharide and polydextrose	1×10^9 CFU per day for 30 days, and 2×10^9 CFU per day for 31–60 days	could prevent rhinoviral infection by modulating the composition of gut microbiota	Luoto <i>et al</i> , 2014
ENDURANCE ATHLETES	<i>L. casei</i> Shirota	6.5×10^9 CFU per day for 20 weeks	- significantly reduced the plasma level of CMV and EBV antibody titers - could improve the immunity against respective viral infection	Gleeson <i>et al</i> , 2016

Table 1.1 Probiotics test in different subjects to show the effects of antiviral activity

3.2 Anti-Inflammatory Activity

It has been shown that different probiotic strains diversely affect the host and its immune system (Ng *et al*, 2009). In different in vitro and ex vivo models as well as in microorganism free mice, their huge ability in the rule of irritation has been totally portrayed. These models display the mistake of the fundamental safe administrative organizations, which sets off a chain of events that results in a provocative response. Certain bacterial strains can affect the gastrointestinal mucosal limit, the stomach luminal environment, and the mucosal immune system (Cristofori *et al*, 2021).

Furthermore, tryptophan, which is gotten from diet, and indolic acid subordinates, which are made by probiotics or gastrointestinal microorganisms, can associate with specific receptors communicated on safe cells to create an anti-inflammatory influence (Venkatesh *et al*, 2014).

Anti-Inflammatory Activity of Probiotics include:

1. Celiac Disease: Gluten is a demonstrated natural trigger for celiac sickness, an intriguing immune system condition. Celiac infection, when remembered to be a phenomenal pediatric malabsorption disease, is presently perceived to be a typical infirmity that can influence various organ system and can be analyzed at whatever stage in life (Green & Cellier, 2007). For most of patients, upper endoscopy with biopsy is performed after serologic testing (frequently for IgA against tissue transglutaminase antibodies first) to affirm the finding of celiac infection. Celiac illness victims need to stick to a thorough, long lasting gluten-free diet (Fasano & Catassi, 2012).

The ability of probiotics to hydrolyze immunogenic gluten peptides has been demonstrated, thus reducing their immunogenicity (Caminero *et al*, 2016; Hill *et al*, 2014; De Angelis *et al*, 2006; Rizzello *et al*, 2007; Francavilla *et al*, 2017). There is evidence that some probiotics can break down or change gluten polypeptides. The conceivable responsibility of the specific probiotic mix VSL#3, which contains eight strains from the species *Bifidobacterium breve* helps with decreasing the hurtfulness of wheat with flouring during deferred development. That assessment observed that the probiotic VSL#3 was very capable at isolating gliadin polypeptides (Fallaniet *et al*, 2010). The discoveries infer that numerous probiotic strains should be used to really battle Album since one probiotic strain alone is lacking to separate gliadin peptides. The probiotic product VSL#3 may therefore offer greater effect in fighting off CD because patients may find it difficult to adhere to a gluten-free diet, such as due to cross-contamination.. (De Sousa Moraes *et al*, 2014).

2. Inflammatory Bowel Diseases: The inflammatory bowel diseases (IBDs), essentially ulcerative colitis and Crohn contamination yet furthermore containing noninfectious aggravations of the colon, have jumbled gastroenterologists and immunologists both from their most important current depictions around 75 to a long time back.. As per an alternate examination group, *Bifidobacterium bifidum* supplementation especially supported the degree of IL-10 and diminished the degree of IL-1 in the colon segments, affirming the inflammatory influence (Kumar *et al*, 2017).

3. Irritable Bowel Syndrome: IBS is a persistent gastrointestinal functional condition. Patients report experiencing stomach pain and abnormal bowel habits, primarily with constipation (IBS-C), diarrhoea (IBS-D), or both (IBS-M) (**Canavan et al, 2014**). The most well-known indications of IBS incorporate repetitive stomach torment, changes in entrapment propensities, and stomach extension (**Lacy et al, 2016; Hyams et al, 2016**). Utilizing a metabolomic approach, the impacts of a probiotic multistrain combination (5 109 feasible cells every one of *Bifidobacterium longum* BORI, *Bifidobacterium bifidum* BGN4, *Bifidobacterium lactis* AD011, *Bifidobacterium infantis* IBS007, and *Lactobacillus acidophilus* AD031) was analyzed in patients with looseness of the bowels prevalent IBS. Consequently, it shows that this probiotic mix diminishes urinary degrees of mixtures connected to digestive aggravation and reduces IBS side effects (**Kim et al, 2020**).
4. Obesity: It is proposed that weight counteraction and the board start in youth, when natural impacts affect an individual's gamble for stoutness in adulthood. Thusly, deciding modifiable variables might support bringing down this gamble. Probiotics are of interest since research has uncovered that they can change the organization of the stomach microbiota and can affect gastrointestinal pathways, the stomach bacterial local area, food admission and craving, body weight and arrangement, and metabolic exercises (**Sanchez et al, 2015; Sanchez et al, 2013**). Organization of matured milk containing *Lactobacillus gasseri* SBT2055 for quite some time brought about a critical decrease of stomach instinctive and subcutaneous fat regions, with normal decreases of 4.6 and 3.3%, separately, as estimated by processed tomography, in a new multicenter, twofold visually impaired, randomized, fake treatment controlled preliminary. Just in the gathering getting dynamic treatment bodied weight and BMI decrease fundamentally, around 1.5% (P 0.001), highlight
5. Parkinson's Disease: Parkinsonism is a clinical disorder portrayed by quake, unbending nature, bradykinesia (gradualness of development), hypokinesia (diminished development), akinesia (loss of development), and poor postural arrangement (Marsden, 1994). Because of the stomach's contribution in PD, including expanded stomach penetrability, gastrointestinal side effects, and irritation, the stomach microbiota may play a part in PD pathogenesis, including alpha-synuclein conglomeration (**Forsyth et al, 2011; Houser et al, 2018**). In a clinical examination on the utilization of probiotics in Parkinson's sickness, 60 patients with the illness were haphazardly relegated to get either a multistrain probiotic (counting *Lactobacillus* and *Bifidobacterium*) or a placebo treatment. The probiotic-treated bunch gave improvement in engine indications and side effects. Higher cancer prevention agent glutathione levels and lower serum C-responsive protein levels were connected to the remedial effect (**Srivastav et al, 2019**).

Probiotics used in the treatment of respiratory infection

Intense respiratory contaminations, especially popular respiratory contaminations, are a significant wellspring of bleakness and mortality in youngsters and grown-ups all over the planet and can likewise be a forerunner to other sicknesses (**Alonso et al, 2012**). The viral respiratory plot diseases welcomed on by rhinoviruses, Covids, and flu that ordinarily lead to aspiratory ailments universally are allocated the most boundless and normal infectivity design. Microbe prompted pneumonia in kids and children expands hospitalisations and fatalities; it normally brings about 120 million cases and around 1 million passings every year (**Bhuiyan et al, 2019**).

Probiotics, prebiotics, phytochemicals, and ordinary antimicrobials, as well as their metabolites, stand apart since the SARS-CoV-2 pandemic. These substances are continually being read up for their ability to stifle infections and decrease their harmful impacts on the host (**Baud et al, 2020**). Inflammasome movement, a natural signalling pathway engaged with guard against a subset of infections, and interferon (IFN) signalling, which is fundamental for reaction against most of infections, are both constrained by stomach microbes (**Abt et al, 2012**). Some *Lactobacillus* and *Bifidobacterium* species decreased the frequency of airways viral infection and enhanced its results (**Budden et al, 2017**).

CONCLUSION

Respiratory viral infections like COVID 19 are still increasing enormously despite many programmes and vaccination drives being implemented to immunize against SARS-CoV-2 which cause severe mortality rates. The sickness' seriousness can go from a minor upper parcel aviation route disease to a serious ongoing irritation of the respiratory plot's mucosa, which in specific cases can prompt multiorgan failure. Fortifying the host immune system is the most ideal way to battle against this sort of diseases. Probiotics offer many benefits, including managing the human stomach's microbial synthesis, upgrading stomach obstruction capability, and setting off defensive invulnerable reactions. Various clinical investigations has exhibited that probiotics like lactobacilli and bifidobacteria are protected. The components behind every probiotic capability should be explained for proficient clinical use as probiotic research moves into the following stage. Understanding the microbiota makeup of Coronavirus patients is likewise a pivotal part of this exploration since it might give new points of view to figuring out the contamination component and disease improvement.

REFERENCES

1. Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020). A novel coronavirus outbreak of global health concern. *The lancet*, 395(10223), 470-473.[https://doi.org/10.1016/S0140-6736\(20\)30185-9](https://doi.org/10.1016/S0140-6736(20)30185-9)
2. Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., ... & Ziebuhr, J. (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature microbiology*, 5(4), 536-544.[doi:10.1038/s41564-020-0695-z](https://doi.org/10.1038/s41564-020-0695-z)
3. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., ... & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *cell*, 181(2), 271-280.<https://doi.org/10.1016/j.cell.2020.02.052>
4. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Zhong, N. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*, 382(18), 1708-1720.
5. Hassan, S. A., Sheikh, F. N., Jamal, S., Ezech, J. K., & Akhtar, A. (2020). Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. *Cureus*, 12(3).[10.7759/cureus.7355](https://doi.org/10.7759/cureus.7355)
6. Cevik, M., Bamford, C. G. G., & Ho, A. (2020). COVID-19 pandemic—a focused review for clinicians. *Clinical Microbiology and Infection*, 26(7), 842-847.<https://doi.org/10.1016/j.cmi.2020.04.023>
7. Eurosurveillance Editorial Team. (2020). Latest updates on COVID-19 from the European Centre for Disease Prevention and Control. *Eurosurveillance*, 25(6), 2002131.
8. Yazdany, J., & Kim, A. H. (2020). Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. *Annals of internal medicine*, 172(11), 754-755.<https://doi.org/10.7326/M20-1334>
9. Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., ... & Albaiu, D. (2020). Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases.<https://doi.org/10.1021/acscentsci.0c00272>
10. López-Moreno, A., & Aguilera, M. (2020). Probiotics dietary supplementation for modulating endocrine and fertility microbiota dysbiosis. *Nutrients*, 12(3), 757.<https://doi.org/10.3390/nu12030757>
11. El Hage, R., Hernandez-Sanabria, E., & Van de Wiele, T. (2017). Emerging trends in “smart probiotics”: functional consideration for the development of novel health and industrial applications. *Frontiers in microbiology*, 8, 1889.<https://doi.org/10.3389/fmicb.2017.01889>
12. Li, Y. C., Chen, Y., & Du, J. (2015). Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation. *The Journal of steroid biochemistry and molecular biology*, 148, 179-183.<https://doi.org/10.1016/j.jsbmb.2015.01.011>
13. Del Pinto, R., Ferri, C., & Cominelli, F. (2017). Vitamin D axis in inflammatory bowel diseases: role, current uses and future perspectives. *International Journal of Molecular Sciences*, 18(11), 2360.<https://doi.org/10.3390/ijms18112360>
14. Khaneghah, A. M., Abhari, K., Eş, I., Soares, M. B., Oliveira, R. B., Hosseini, H., ... & Sant’Ana, A. S. (2020). Interactions between probiotics and pathogenic microorganisms in hosts and foods: A review. *Trends in Food Science & Technology*, 95, 205-218.<https://doi.org/10.1016/j.tifs.2019.11.022>
15. Rajput, S., Paliwal, D., Naithani, M., Kothari, A., Meena, K., & Rana, S. (2021). COVID-19 and gut microbiota: a potential connection. *Indian Journal of Clinical Biochemistry*, 36, 266-277.<https://doi.org/10.1007/s12291-020-00948-9>
16. Grudzien, M., & Rapak, A. (2018). Effect of natural compounds on NK cell activation. *Journal of Immunology Research*, 2018.<https://doi.org/10.1155/2018/4868417>
17. Azad, M., Kalam, A., Sarker, M., & Wan, D. (2018). Immunomodulatory effects of probiotics on cytokine profiles. *BioMed research international*, 2018.<https://doi.org/10.1155/2018/8063647>
18. Wang, Y., Li, X., Ge, T., Xiao, Y., Liao, Y., Cui, Y., ... & Zhang, T. (2016). Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. *Medicine*, 95(31).[10.1097/MD.0000000000004509](https://doi.org/10.1097/MD.0000000000004509)
19. Mortaz, E., Adcock, I. M., Folkerts, G., Barnes, P. J., Paul Vos, A., & Garssen, J. (2013). Probiotics in the management of lung diseases. *Mediators of inflammation*, 2013.<https://doi.org/10.1155/2013/751068>
20. Sadiq, F. A. (2021). Is it time for microbiome-based therapies in viral infections?. *Virus Research*, 291, 198203.<https://doi.org/10.1016/j.virusres.2020.198203>
21. Antunes, A. E., Vinderola, G., Xavier-Santos, D., & Sivieri, K. (2020). Potential contribution of beneficial microbes to face the COVID-19 pandemic. *Food research international*, 136, 109577.<https://doi.org/10.1016/j.foodres.2020.109577>
22. Mack, D. R. (2005). Probiotics: mixed messages. *Canadian Family Physician*, 51(11), 1455.
23. Bezirtoglou, E., & Stavropoulou, E. (2011). Immunology and probiotic impact of the newborn and young children intestinal microflora. *Anaerobe*, 17(6), 369-374.<https://doi.org/10.1016/j.anaerobe.2011.03.010>
24. Marinova, V. Y., Rasheva, I. K., Kizheva, Y. K., Dermenzhieva, Y. D., & Hristova, P. K. (2019). Microbiological quality of probiotic dietary supplements. *Biotechnology & Biotechnological Equipment*, 33(1), 834-841.<https://doi.org/10.1080/13102818.2019.1621208>

25. Wan, L. Y. M., Chen, Z. J., Shah, N. P., & El-Nezami, H. (2016). Modulation of intestinal epithelial defense responses by probiotic bacteria. *Critical reviews in food science and nutrition*, 56(16), 2628-2641. <https://doi.org/10.1080/10408398.2014.905450>
26. Rodriguez, W. J., Kim, H. W., Brandt, C. D., Bise, B., Kapikian, A. Z., Chanock, R. M., ... & Parrott, R. H. (1980). Rotavirus gastroenteritis in the Washington, DC, area: incidence of cases resulting in admission to the hospital. *American Journal of Diseases of Children*, 134(8), 777-779. [10.1001/archpedi.1980.02130200047015](https://doi.org/10.1001/archpedi.1980.02130200047015)
27. Tate, J. E., Burton, A. H., Boschi-Pinto, C., Parashar, U. D., World Health Organization–Coordinated Global Rotavirus Surveillance Network, Agocs, M., ... & Paladini, F. (2016). Global, regional, and national estimates of rotavirus mortality in children < 5 years of age, 2000–2013. *Clinical Infectious Diseases*, 62(suppl_2), S96-S105. <https://doi.org/10.1093/cid/civ1013>
28. Ma, C., Wu, X., Nawaz, M., Li, J., Yu, P., Moore, J. E., & Xu, J. (2011). Molecular characterization of fecal microbiota in patients with viral diarrhea. *Current microbiology*, 63(3), 259. <https://doi.org/10.1007/s00284-011-9972-7>
29. Pant, N., Marcotte, H., Brüssow, H., Svensson, L., & Hammarström, L. (2007). Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. *BMC microbiology*, 7(1), 1-9. <https://doi.org/10.1186/1471-2180-7-86>
30. Lehtoranta, L., Pitkäranta, A., & Korpela, R. (2014). Probiotics in respiratory virus infections. *European journal of clinical microbiology & infectious diseases*, 33, 1289-1302. <https://doi.org/10.1007/s10096-014-2086-y>
31. Jung, Y. J., Lee, Y. T., Ngo, V. L., Cho, Y. H., Ko, E. J., Hong, S. M., ... & Kang, S. M. (2017). Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection. *Scientific reports*, 7(1), 17360. <https://doi.org/10.1038/s41598-017-17487-8>
32. Araujo, G. V. D., Oliveira Junior, M. H. D., Peixoto, D. M., & Sarinho, E. S. C. (2015). Probiotics for the treatment of upper and lower respiratory-tract infections in children: systematic review based on randomized clinical trials. *Jornal de pediatria*, 91, 413-427. <https://doi.org/10.1016/j.jped.2015.03.002>
33. Oliva, S., Di Nardo, G., Ferrari, F., Mallardo, S., Rossi, P., Patrizi, G., ... & Stronati, L. (2012). Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. *Alimentary pharmacology & therapeutics*, 35(3), 327-334. <https://doi.org/10.1111/j.1365-2036.2011.04939.x>
34. Fooks, L. J., & Gibson, G. R. (2002). Probiotics as modulators of the gut flora. *British Journal of Nutrition*, 88(S1), s39-s49. <https://doi.org/10.1079/BJN2002628>
35. McAuliffe, O., Cano, R. J., & Klaenhammer, T. R. (2005). Genetic analysis of two bile salt hydrolase activities in Lactobacillus acidophilus NCFM. *Applied and environmental microbiology*, 71(8), 4925-4929. <https://doi.org/10.1128/AEM.71.8.4925-4929.2005>
36. Lye, H. S., Rahmat-Ali, G. R., & Liong, M. T. (2010). Mechanisms of cholesterol removal by lactobacilli under conditions that mimic the human gastrointestinal tract. *International Dairy Journal*, 20(3), 169-175. <https://doi.org/10.1016/j.idairyj.2009.10.003>
37. Ishimwe, N., Daliri, E. B., Lee, B. H., Fang, F., & Du, G. (2015). The perspective on cholesterol-lowering mechanisms of probiotics. *Molecular nutrition & food research*, 59(1), 94-105. <https://doi.org/10.1002/mnfr.201400548>
38. Lee, I. (2014). Critical pathogenic steps to high risk Helicobacter pylori gastritis and gastric carcinogenesis. *World Journal of Gastroenterology: WJG*, 20(21), 6412. [10.3748/wjg.v20.i21.6412](https://doi.org/10.3748/wjg.v20.i21.6412)
39. Waigankar, S. S., & Patel, V. (2011). Role of probiotics in urogenital healthcare. *Journal of mid-life health*, 2(1), 5-10. [10.4103/0976-7800.83253](https://doi.org/10.4103/0976-7800.83253)
40. Commane, D., Hughes, R., Shortt, C., & Rowland, I. (2005). The potential mechanisms involved in the anti-carcinogenic action of probiotics. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, 591(1-2), 276-289. <https://doi.org/10.1016/j.mrfmmm.2005.02.027>
41. Reid, G., & Bruce, A. W. (2006). Probiotics to prevent urinary tract infections: the rationale and evidence. *World journal of urology*, 24, 28-32. <https://doi.org/10.1007/s00345-005-0043-1>
42. Vujic, G., Knez, A. J., Stefanovic, V. D., & Vrbancic, V. K. (2013). Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 168(1), 75-79. <https://doi.org/10.1016/j.ejogrb.2012.12.031>
43. Reid, G., Beuerman, D., Heinemann, C., & Bruce, A. W. (2001). Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. *FEMS Immunology & Medical Microbiology*, 32(1), 37-41. <https://doi.org/10.1111/j.1574-695X.2001.tb00531.x>
44. Elavarasu, S., Jayapalan, P., & Murugan, T. (2012). Bugs that debugs: Probiotics. *Journal of Pharmacy & Bioallied Sciences*, 4(Suppl 2), S319. [10.4103/0975-7406.100286](https://doi.org/10.4103/0975-7406.100286)

45. Banas, J. A., & Popp, E. T. (2013). Recovery of viable bacteria from probiotic products that target oral health. *Probiotics and antimicrobial proteins*, 5, 227-231. <https://doi.org/10.1007/s12602-013-9142-2>
46. Barling, P. M. (2012). Lactose tolerance and intolerance in Malaysians. *IeJSME*, 6(Suppl 1), S12-S23.
47. Ibrahim, S. A., & O'Sullivan, D. J. (2000). Use of chemical mutagenesis for the isolation of food grade β -galactosidase overproducing mutants of bifidobacteria, lactobacilli and *Streptococcus thermophilus*. *Journal of dairy science*, 83(5), 923-930. [https://doi.org/10.3168/jds.S0022-0302\(00\)74955-1](https://doi.org/10.3168/jds.S0022-0302(00)74955-1)
48. Goh, Y. J., & Klaenhammer, T. R. (2013). A functional glycogen biosynthesis pathway in *L. actobacillus acidophilus*: expression and analysis of the glg operon. *Molecular microbiology*, 89(6), 1187-1200. <https://doi.org/10.1111/mmi.12338>
49. Foxx-Orenstein, A. E., & Chey, W. D. (2012). Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders. *The American Journal of Gastroenterology Supplements*, 1(1), 41. [10.1038/ajgsup.2012.8](https://doi.org/10.1038/ajgsup.2012.8)
50. McFarland, L. V. (2010). Probiotics and diarrhea. *Annals of Nutrition & Metabolism*, 57, 10.
51. Baek, Y. J., & Lee, B. H. (2009). Probiotics and prebiotics as bioactive components in dairy products. *Bioactive Components in Milk and Dairy Products*, 287.
52. Cain, K. C., Headstrom, P., Jarrett, M. E., Motzer, S. A., Park, H., Burr, R. L., ... & Heitkemper, M. M. (2006). Abdominal pain impacts quality of life in women with irritable bowel syndrome. *Official journal of the American College of Gastroenterology* | *ACG*, 101(1), 124-132.
53. Ford, A. C., Forman, D., Bailey, A. G., Axon, A. T., & Moayyedi, P. (2007). Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. *Gut*, 56(3), 321-327. <https://doi.org/10.1136/gut.2006.099846>
54. Cremonini, F., & Talley, N. J. (2005). Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. *Gastroenterology Clinics*, 34(2), 189-204. <https://doi.org/10.1016/j.gtc.2005.02.008>
55. McFarland, L. V., & Dublin, S. (2008). Meta-analysis of probiotics for the treatment of irritable bowel syndrome. *World journal of gastroenterology: WJG*, 14(17), 2650. [10.3748/wjg.14.2650](https://doi.org/10.3748/wjg.14.2650)
56. Sanders, M. E., Guarner, F., Guerrant, R., Holt, P. R., Quigley, E. M., Sartor, R. B., ... & Mayer, E. A. (2013). An update on the use and investigation of probiotics in health and disease. *Gut*, 62(5), 787-796. <https://doi.org/10.1136/gutjnl-2012-302504>
57. Black, R. E., Cousens, S., Johnson, H. L., Lawn, J. E., Rudan, I., Bassani, D. G., ... & Mathers, C. (2010). Global, regional, and national causes of child mortality in 2008: a systematic analysis. *The lancet*, 375(9730), 1969-1987. [https://doi.org/10.1016/S0140-6736\(10\)60549-1](https://doi.org/10.1016/S0140-6736(10)60549-1)
58. Guarino, A., Guandalini, S., & Vecchio, A. L. (2015). Probiotics for prevention and treatment of diarrhea. *Journal of clinical gastroenterology*, 49, S37-S45. [10.1097/MCG.0000000000000349](https://doi.org/10.1097/MCG.0000000000000349)
59. Saavedra, J. M., Bauman, N. A., Perman, J. A., Yolken, R. H., & Oung, I. (1994). Feeding of *Bifidobacterium bifidum* and *Streptococcus thermophilus* to infants in hospital for prevention of diarrhoea and shedding of rotavirus. *The lancet*, 344(8929), 1046-1049. [https://doi.org/10.1016/S0140-6736\(94\)91708-6](https://doi.org/10.1016/S0140-6736(94)91708-6)
60. Barraud, D., Blard, C., Hein, F., Marçon, O., Cravoisy, A., Nace, L., ... & Gibot, S. (2010). Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. *Intensive care medicine*, 36, 1540-1547. <https://doi.org/10.1007/s00134-010-1927-0>
61. Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., ... & Gooszen, H. G. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. *The Lancet*, 371(9613), 651-659. [https://doi.org/10.1016/S0140-6736\(08\)60207-X](https://doi.org/10.1016/S0140-6736(08)60207-X)
62. Goldin, B. R., & Gorbach, S. L. (1980). Effect of *Lactobacillus acidophilus* dietary supplements on 1, 2-dimethylhydrazine dihydrochloride-induced intestinal cancer in rats. *Journal of the National Cancer Institute*, 64(2), 263-265. <https://doi.org/10.1093/jnci/64.2.263>
63. Thirabunyanon, M., Boonprasom, P., & Niamsup, P. (2009). Probiotic potential of lactic acid bacteria isolated from fermented dairy milks on antiproliferation of colon cancer cells. *Biotechnology letters*, 31, 571-576. <https://doi.org/10.1007/s10529-008-9902-3>
64. Sanderson, I. R., & Walker, W. A. (1993). Uptake and transport of macromolecules by the intestine: possible role in clinical disorders (an update). *Gastroenterology*, 104(2), 622-639. [https://doi.org/10.1016/0016-5085\(93\)90436-G](https://doi.org/10.1016/0016-5085(93)90436-G)
65. Matsuzaki, T., Yamazaki, R., Hashimoto, S., & Yokokura, T. (1998). The effect of oral feeding of *Lactobacillus casei* strain Shirota on immunoglobulin E production in mice. *Journal of Dairy Science*, 81(1), 48-53. [https://doi.org/10.3168/jds.S0022-0302\(98\)75549-3](https://doi.org/10.3168/jds.S0022-0302(98)75549-3)
66. Matsuzaki, T., & Chin, J. (2000). Modulating immune responses with probiotic bacteria. *Immunology and cell biology*, 78(1), 67-73. <https://doi.org/10.1046/j.1440-1711.2000.00887.x>

67. Madsen, K., Cornish, A., Soper, P., McKaigney, C., Jijon, H., Yachimec, C., ... & De Simone, C. (2001). Probiotic bacteria enhance murine and human intestinal epithelial barrier function. *Gastroenterology*, 121(3), 580-591.<https://doi.org/10.1053/gast.2001.27224>
68. Chiang, B. L., Sheih, Y. H., Wang, L. H., Liao, C. K., & Gill, H. S. (2000). Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (*Bifidobacterium lactis* HN019): optimization and definition of cellular immune responses. *European journal of clinical nutrition*, 54(11), 849-855.<https://doi.org/10.1038/sj.ejcn.1601093>
69. Gill, H. S., Rutherford, K. J., Cross, M. L., & Gopal, P. K. (2001). Enhancement of immunity in the elderly by dietary supplementation with the probiotic *Bifidobacterium lactis* HN019. *The American journal of clinical nutrition*, 74(6), 833-839.<https://doi.org/10.1093/ajcn/74.6.833>
70. Cross, M. L., Mortensen, R. R., Kudsk, J., & Gill, H. S. (2002). Dietary intake of *Lactobacillus rhamnosus* HN001 enhances production of both Th1 and Th2 cytokines in antigen-primed mice. *Medical microbiology and immunology*, 191, 49-53.<https://doi.org/10.1007/s00430-002-0112-7>
71. Helenius, A. (2018). Virus entry: looking back and moving forward. *Journal of molecular biology*, 430(13), 1853-1862.<https://doi.org/10.1016/j.jmb.2018.03.034>
72. Hardy, H., Harris, J., Lyon, E., Beal, J., & Foey, A. D. (2013). Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. *Nutrients* 5: 1869–1912.<https://doi.org/10.3390/nu5061869>
73. Villena, J., Vizoso-Pinto, M. G., & Kitazawa, H. (2016). Intestinal innate antiviral immunity and immunobiotics: beneficial effects against rotavirus infection. *Frontiers in immunology*, 7, 563.<https://doi.org/10.3389/fimmu.2016.00563>
74. Aslam, H., Green, J., Jacka, F. N., Collier, F., Berk, M., Pasco, J., & Dawson, S. L. (2020). Fermented foods, the gut and mental health: a mechanistic overview with implications for depression and anxiety. *Nutritional neuroscience*, 23(9), 659-671.<https://doi.org/10.1080/1028415X.2018.1544332>
75. Verhoeven, V., Renard, N., Makar, A., Van Royen, P., Bogers, J. P., Lardon, F., ... & Baay, M. (2013). Probiotics enhance the clearance of human papillomavirus-related cervical lesions. *European journal of cancer prevention*, 22(1), 46-51.
76. Khusro, A., Aarti, C., Barbabosa-Pilego, A., & Sánchez-Aparicio, P. (2018). Outbreak of Zika virus pathogenesis and quest of its vaccine development: Where do we stand now?. *Microbial pathogenesis*, 116, 289-295.<https://doi.org/10.1016/j.micpath.2018.02.001>
77. Khusro, A., Aarti, C., Pliego, A. B., & Cipriano-Salazar, M. (2020). Hendra virus infection in horses: A review on emerging mystery paramyxovirus. *Journal of Equine Veterinary Science*, 91, 103149.<https://doi.org/10.1016/j.jevs.2020.103149>
78. Khusro, A., Aarti, C., Rivas-Caceres, R. R., & Barbabosa-Pliego, A. (2020). Equine herpesvirus-1 infection in horses: Recent updates on its pathogenicity, vaccination, and preventive management strategies. *Journal of equine veterinary science*, 87, 102923.<https://doi.org/10.1016/j.jevs.2020.102923>
79. Infusino, F., Marazzato, M., Mancone, M., Fedele, F., Mastroianni, C. M., Severino, P., ... & d'Ettore, G. (2020). Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: a scoping review. *Nutrients*, 12(6), 1718.<https://doi.org/10.3390/nu12061718>
80. Sundararaman, A., Ray, M., Ravindra, P. V., & Halami, P. M. (2020). Role of probiotics to combat viral infections with emphasis on COVID-19. *Applied microbiology and biotechnology*, 104, 8089-8104.<https://doi.org/10.1007/s00253-020-10832-4>
81. Berggren, A., Lazou Ahrén, I., Larsson, N., & Önning, G. (2011). Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. *European journal of nutrition*, 50, 203-210.<https://doi.org/10.1007/s00394-010-0127-6>
82. Jespersen, L., Tarnow, I., Eskesen, D., Morberg, C. M., Michelsen, B., Bügel, S., ... & Calder, P. C. (2015). Effect of *Lactobacillus paracasei* subsp. *paracasei*, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. *The American journal of clinical nutrition*, 101(6), 1188-1196.<https://doi.org/10.3945/ajcn.114.103531>
83. Przemska-Kosicka, A., Childs, C. E., Enani, S., Maidens, C., Dong, H., Dayel, I. B., ... & Yaqoob, P. (2016). Effect of a synbiotic on the response to seasonal influenza vaccination is strongly influenced by degree of immunosenescence. *Immunity & Ageing*, 13, 1-12.<https://doi.org/10.1186/s12979-016-0061-4>
84. Baron, M. (2009). A patented strain of *Bacillus coagulans* increased immune response to viral challenge. *Postgraduate medicine*, 121(2), 114-118.<https://doi.org/10.3810/pgm.2009.03.1971>
85. Fang, S. B., Lee, H. C., Hu, J. J., Hou, S. Y., Liu, H. L., & Fang, H. W. (2009). Dose-dependent effect of *Lactobacillus rhamnosus* on quantitative reduction of faecal rotavirus shedding in children. *Journal of tropical pediatrics*, 55(5), 297-301.<https://doi.org/10.1093/tropej/fmp001>

86. Luoto, R., Ruuskanen, O., Waris, M., Kalliomäki, M., Salminen, S., & Isolauri, E. (2014). Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*, 133(2), 405-413. <https://doi.org/10.1016/j.jaci.2013.08.020>
87. Gleeson, M., Bishop, N. C., & Struszcak, L. (2016). Effects of Lactobacillus casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes: a placebo-controlled, randomized trial. *European journal of applied physiology*, 116, 1555-1563. <https://doi.org/10.1007/s00421-016-3415-x>
88. Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J., & Knight, S. C. (2009). Mechanisms of action of probiotics: recent advances. *Inflammatory bowel diseases*, 15(2), 300-310. <https://doi.org/10.1002/ibd.20602>
89. Cristofori, F., Dargenio, V. N., Dargenio, C., Miniello, V. L., Barone, M., & Francavilla, R. (2021). Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. *Frontiers in immunology*, 12, 578386. <https://doi.org/10.3389/fimmu.2021.578386>
90. Venkatesh, M., Mukherjee, S., Wang, H., Li, H., Sun, K., Benechet, A. P., ... & Mani, S. (2014). Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. *Immunity*, 41(2), 296-310. <https://doi.org/10.1016/j.immuni.2014.06.014>
91. Green, P. H., & Cellier, C. (2007). Celiac disease. *New england journal of medicine*, 357(17), 1731-1743. [10.1056/NEJMr071600](https://doi.org/10.1056/NEJMr071600)
92. Fasano, A., & Catassi, C. (2012). Celiac disease. *New England Journal of Medicine*, 367(25), 2419-2426. [10.1056/NEJMc1113994](https://doi.org/10.1056/NEJMc1113994)
93. Caminero, A., Galipeau, H. J., McCarville, J. L., Johnston, C. W., Bernier, S. P., Russell, A. K., ... & Verdu, E. F. (2016). Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity. *Gastroenterology*, 151(4), 670-683. <https://doi.org/10.1053/j.gastro.2016.06.041>
94. Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., ... & Sanders, M. E. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature reviews Gastroenterology & hepatology*. <https://doi.org/10.1038/nrgastro.2014.66>
95. De Angelis, M., Rizzello, C. G., Fasano, A., Clemente, M. G., De Simone, C., Silano, M., ... & Gobbetti, M. (2006). VSL# 3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue probiotics and gluten intolerance. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, 1762(1), 80-93. <https://doi.org/10.1016/j.bbadis.2005.09.008>
96. Rizzello, C. G., De Angelis, M., Di Cagno, R., Camarica, A., Silano, M., Losito, I., ... & Gobbetti, M. (2007). Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac disease. *Applied and environmental microbiology*, 73(14), 4499-4507. <https://doi.org/10.1128/AEM.00260-07>
97. Francavilla, R., De Angelis, M., Rizzello, C. G., Cavallo, N., Dal Bello, F., & Gobbetti, M. (2017). Selected probiotic lactobacilli have the capacity to hydrolyze gluten peptides during simulated gastrointestinal digestion. *Applied and environmental microbiology*, 83(14), e00376-17. <https://doi.org/10.1128/AEM.00376-17>
98. Fallani, M., Young, D., Scott, J., Norin, E., Amarri, S., Adam, R., ... & INFABIO team. (2010). Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics. *Journal of pediatric gastroenterology and nutrition*, 51(1), 77-84. [10.1097/MPG.0b013e3181d1b11e](https://doi.org/10.1097/MPG.0b013e3181d1b11e)
99. de Sousa Moraes, L. F., Grzeskowiak, L. M., de Sales Teixeira, T. F., & Gouveia Peluzio, M. D. C. (2014). Intestinal microbiota and probiotics in celiac disease. *Clinical microbiology reviews*, 27(3), 482-489. <https://doi.org/10.1128/CMR.00106-13>
100. Laparra, J. M., Olivares, M., Gallina, O., & Sanz, Y. (2012). Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model. *PLoS One*, 7(2), e30744.
101. Olivares, M., Laparra, M., & Sanz, Y. (2011). Influence of Bifidobacterium longum CECT 7347 and gliadin peptides on intestinal epithelial cell proteome. *Journal of agricultural and food chemistry*, 59(14), 7666-7671. <https://doi.org/10.1021/jf201212m>
102. Kumar, C. S., Reddy, K. K., Boobalan, G., Reddy, A. G., Chowdhary, C. S. R., Vinoth, A., ... & Rao, G. S. (2017). Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. *Research in veterinary science*, 110, 40-46. <https://doi.org/10.1016/j.rvsc.2016.10.010>
103. Canavan, C., West, J., & Card, T. (2014). The epidemiology of irritable bowel syndrome. *Clinical epidemiology*, 71-80.
104. Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016). Bowel disorders. *Gastroenterology*, 150(6), 1393-1407. <https://doi.org/10.1053/j.gastro.2016.02.031>
105. Hyams, J. S., Di Lorenzo, C., Saps, M., Shulman, R. J., Staiano, A., & van Tilburg, M. (2016). Childhood functional gastrointestinal disorders: child/adolescent. *Gastroenterology*, 150(6), 1456-1468. <https://doi.org/10.1053/j.gastro.2016.02.015>

106. Kim, J., Cho, K., Kim, J. S., Jung, H. C., Kim, B., Park, M. S., ... & Hong, K. S. (2020). Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial. *Food Science and Biotechnology*, 29, 837-844. <https://doi.org/10.1007/s10068-019-00717-2>
107. Sanchez, M., Panahi, S., & Tremblay, A. (2015). Childhood obesity: a role for gut microbiota?. *International journal of environmental research and public health*, 12(1), 162-175. <https://doi.org/10.3390/ijerph120100162>
108. Salaj, R., Štofilová, J., Šoltesová, A., Hertelyová, Z., Hijová, E., Bertková, I., ... & Bomba, A. (2013). The effects of two *Lactobacillus plantarum* strains on rat lipid metabolism receiving a high fat diet. *The Scientific World Journal*, 2013. <https://doi.org/10.1155/2013/135142>
109. Kadooka, Y., Sato, M., Imaizumi, K., Ogawa, A., Ikuyama, K., Akai, Y., ... & Tsuchida, T. (2010). Regulation of abdominal adiposity by probiotics (*Lactobacillus gasseri* SBT2055) in adults with obese tendencies in a randomized controlled trial. *European journal of clinical nutrition*, 64(6), 636-643. <https://doi.org/10.1038/ejcn.2010.19>
110. Marsden, C. D. (1994). Parkinson's disease. *Journal of Neurology, Neurosurgery, and Psychiatry*, 57(6), 672. [10.1136/jnnp.57.6.672](https://doi.org/10.1136/jnnp.57.6.672)
111. Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., ... & Keshavarzian, A. (2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. *PloS one*, 6(12), e28032.
112. Houser, M. C., Chang, J., Factor, S. A., Molho, E. S., Zabetian, C. P., Hill-Burns, E. M., ... & Tansey, M. G. (2018). Stool immune profiles evince gastrointestinal inflammation in Parkinson's disease. *Movement Disorders*, 33(5), 793-804. <https://doi.org/10.1002/mds.27326>
113. Srivastav, S., Neupane, S., Bhurtel, S., Katila, N., Maharjan, S., Choi, H., ... & Choi, D. Y. (2019). Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. *The Journal of Nutritional Biochemistry*, 69, 73-86. <https://doi.org/10.1016/j.jnutbio.2019.03.021>
114. Alonso, W. J., Laranjeira, B. J., Pereira, S. A., Florencio, C. M., Moreno, E. C., Miller, M. A., ... & Moura, F. E. (2012). Comparative dynamics, morbidity and mortality burden of pediatric viral respiratory infections in an equatorial city. *The Pediatric infectious disease journal*, 31(1), e9. [10.1097/INF.0b013e31823883be](https://doi.org/10.1097/INF.0b013e31823883be)
115. Bhuiyan, M. U., Blyth, C. C., West, R., Lang, J., Rahman, T., Granland, C., ... & Snelling, T. L. (2019). Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children. *BMC pulmonary medicine*, 19, 1-9. <https://doi.org/10.1186/s12890-019-0835-5>
116. Abt, M. C., Osborne, L. C., Monticelli, L. A., Doering, T. A., Alenghat, T., Sonnenberg, G. F., ... & Artis, D. (2012). Commensal bacteria calibrate the activation threshold of innate antiviral immunity. *Immunity*, 37(1), 158-170. <https://doi.org/10.1016/j.immuni.2012.04.011>
117. Budden, K. F., Gellatly, S. L., Wood, D. L., Cooper, M. A., Morrison, M., Hugenholtz, P., & Hansbro, P. M. (2017). Emerging pathogenic links between microbiota and the gut-lung axis. *Nature Reviews Microbiology*, 15(1), 55-63. <https://doi.org/10.1038/nrmicro.2016.142>